ValuEngine upgraded shares of Nektar Therapeutics (NASDAQ:NKTR) from a sell rating to a hold rating in a research note published on Friday morning.

Other analysts have also issued research reports about the stock. BidaskClub raised shares of Nektar Therapeutics from a sell rating to a hold rating in a report on Thursday, August 17th. Jefferies Group LLC reaffirmed a buy rating and set a $23.00 price objective on shares of Nektar Therapeutics in a report on Friday, August 18th. HC Wainwright assumed coverage on shares of Nektar Therapeutics in a report on Monday, August 7th. They set a buy rating and a $31.00 price objective for the company. Zacks Investment Research lowered shares of Nektar Therapeutics from a buy rating to a hold rating in a report on Friday, August 11th. Finally, William Blair reaffirmed an outperform rating on shares of Nektar Therapeutics in a report on Tuesday, July 18th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $26.10.

Nektar Therapeutics (NASDAQ NKTR) opened at 21.60 on Friday. Nektar Therapeutics has a one year low of $11.41 and a one year high of $24.88. The company’s market capitalization is $3.38 billion. The company has a 50-day moving average price of $20.25 and a 200-day moving average price of $19.01.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by $0.04. The firm had revenue of $34.60 million for the quarter, compared to analyst estimates of $33.64 million. Nektar Therapeutics had a negative return on equity of 1,223.34% and a negative net margin of 157.14%. The business’s quarterly revenue was up 5.5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.36) EPS. Equities research analysts anticipate that Nektar Therapeutics will post ($0.94) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/05/valuengine-upgrades-nektar-therapeutics-nktr-to-hold.html.

In related news, SVP Ivan P. Gergel sold 54,920 shares of the firm’s stock in a transaction that occurred on Tuesday, July 18th. The shares were sold at an average price of $21.10, for a total value of $1,158,812.00. Following the completion of the sale, the senior vice president now owns 98,492 shares of the company’s stock, valued at $2,078,181.20. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Howard W. Robin sold 91,714 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $19.26, for a total transaction of $1,766,411.64. Following the completion of the sale, the chief executive officer now directly owns 152,504 shares of the company’s stock, valued at approximately $2,937,227.04. The disclosure for this sale can be found here. In the last three months, insiders sold 237,629 shares of company stock valued at $4,820,217. 5.44% of the stock is currently owned by company insiders.

Several institutional investors have recently modified their holdings of NKTR. BlackRock Inc. increased its holdings in shares of Nektar Therapeutics by 180,432.9% in the first quarter. BlackRock Inc. now owns 20,035,546 shares of the biopharmaceutical company’s stock valued at $470,234,000 after purchasing an additional 20,024,448 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Nektar Therapeutics in the second quarter valued at approximately $34,661,000. PointState Capital LP increased its holdings in shares of Nektar Therapeutics by 281.7% in the second quarter. PointState Capital LP now owns 1,731,000 shares of the biopharmaceutical company’s stock valued at $33,841,000 after purchasing an additional 1,277,500 shares in the last quarter. MARSHALL WACE ASIA Ltd acquired a new stake in shares of Nektar Therapeutics in the first quarter valued at approximately $23,580,000. Finally, Marshall Wace North America L.P. acquired a new stake in shares of Nektar Therapeutics in the first quarter valued at approximately $23,580,000. 95.15% of the stock is owned by institutional investors and hedge funds.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Stock Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related stocks with our FREE daily email newsletter.